Company Overview of Mimetogen Pharmaceuticals Inc.
Mimetogen Pharmaceuticals Inc., a biotechnology company, engages in designing and developing small molecule drugs to treat dry eye, glaucoma, age-related macular degeneration, keratoconus, and retinitis pigmentosa. The company’s products mimic the effects of neurotrophin proteins that help to maintain the health and growth of cells and tissues found in the eye. It provides tyrosine kinase agonists that prevent neuronal death; small molecule tyrosine kinase receptor agonists, which stimulates mucin secretion from conunctival goblet cells; and small molecule neurotrophin mimetics that rescues retinal pigment epithelial cells from oxidative stress-induced apoptosis. The company was founded in 2...
1000 de La Gauchetière Street West
Montreal, QC H3B 5H4
Founded in 2004
Key Executives for Mimetogen Pharmaceuticals Inc.
Chief Executive Officer, President and Director
Chief Financial Officer and Vice President of Finance
Senior Director - Drug Discovery
Senior Scientist - Medicinal Chemistry
Compensation as of Fiscal Year 2015.
Mimetogen Pharmaceuticals Inc. Key Developments
Allergan plc Enters into Licensing Agreement with Mimetogen Pharmaceuticals to Develop and Commercialize Tavilermide (MIM-D3) Topical Dry Eye Treatment
Nov 4 15
Allergan plc announced that its wholly owned subsidiary has entered into an exclusive licensing agreement with Mimetogen Pharmaceuticals to develop and commercialize tavilermide (MIM-D3), a topical formulation of a novel small molecule TrkA agonist for the treatment of dry eye disease. Under the terms of the agreement, Allergan will make an upfront payment of $50 million to Mimetogen and will fund phase 3 development of tavilermide. Mimetogen will additionally be entitled to receive potential milestone payments and royalties based on commercialization of the product. Tavilermide is a small cyclic peptidomimetic of NGF, a naturally occurring protein in the eye responsible for the maintenance of corneal nerves and epithelium. Tavilermide is differentiated from other investigational therapies in dry eye disease because it induces the production of mucin, a naturally occurring component of the tear film, and works upstream prior to inflammation.
Mimetogen Pharmaceuticals Inc. Announces Topline Results of its Second Clinical Study with MIM-D3 for the Treatment of Dry Eye Syndrome
Sep 9 14
Mimetogen Pharmaceuticals Inc. announced positive top line data from its second clinical study (Study Designation MIM-725) with MIM-D3, its lead drug for the treatment of dry eye syndrome. The trial demonstrated significant improvements in both signs and symptoms with 1% MIM-D3 versus placebo, together with excellent safety, comfort and tolerability profiles. Mimetogen has completed its initial analysis of the data and met with the FDA in order to confirm the outstanding requirements for the remainder of the clinical development plan. The 403-patient study (ClinicalTrials.gov Identifier: NCT01960010) utilized Ora's Controlled Adverse Environment (CAE(SM)) chamber to measure dry eye patients' ability to withstand a stressful drying environment on the eye, and patient diaries to measure the severity of their dry eye symptoms over the course of the study. In the study, MIM-D3 successfully demonstrated superiority over placebo in the pre-specified endpoints of both central and total corneal fluorescein staining (change from pre to post CAE) at week 8 (p = 0.0134 and p = 0.0500, respectively) as measured via the Ora Calibra(TM) Scale. MIM-D3 also significantly improved common vision-related function symptoms of dry eye disease as measured via the OSDI(R) questionnaire. The mean blurred vision, reading and watching TV scores were lower in the MIM-D3 group than in the respective placebo groups at week 8 (p = 0.0393, p = 0.0433 and p = 0.0046, respectively). MIM-D3 was comfortable, well tolerated and there were no unexpected or serious ocular adverse events. The most commonly reported ocular adverse events were reduction of visual acuity (MIM-D3, 3%; Placebo, 3%); instillation site pain (MIM-D3 1%; placebo, 1.5%) and eye irritation (MIM-D3, 0%; Placebo, 1.5%). All adverse ocular events were mild and transient in nature.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries